Fig. 5.

MTX-LNC treatment decreases the percentage of T lymphocytes in the glioblastoma microenvironment. Rats with implanted glioblastoma were treated with 1.0 mg/kg/day MTX-LNCs for 10 days. After tumor dissociation, the frequency of T lymphocytes was determined by immunostaining followed by flow cytometry. The percentages of T-helper (CD3⁺CD4⁺) (a), T-cytotoxic (CD3⁺CD8⁺) (b), and T-regulatory (CD4⁺CD25^high, represented in the upper picture) (c) lymphocytes were determined. CD39 expression was also analyzed as a third marker of Treg lymphocytes (d). The values represent the mean ± SEM from at least four animals. Asterisk indicates a significant difference from the control group (p < 0.05) as determined by Student’s t test